973 related articles for article (PubMed ID: 29307283)
1. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
2. Featured Article: Serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
[TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
[TBL] [Abstract][Full Text] [Related]
4. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
McLaughlin PJ; McHugh DP; Magister MJ; Zagon IS
BMC Immunol; 2015 Apr; 16():24. PubMed ID: 25906771
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Brain Res Bull; 2017 Sep; 134():1-9. PubMed ID: 28647454
[TBL] [Abstract][Full Text] [Related]
6. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
[TBL] [Abstract][Full Text] [Related]
7. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
8. Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1323-1330. PubMed ID: 30541348
[TBL] [Abstract][Full Text] [Related]
9. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Rahn KA; McLaughlin PJ; Zagon IS
Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
[TBL] [Abstract][Full Text] [Related]
10. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
11. [Met
Patel C; Meadowcroft MD; Zagon IS; McLaughlin PJ
Brain Res Bull; 2020 Dec; 165():246-252. PubMed ID: 33141073
[TBL] [Abstract][Full Text] [Related]
12. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
Patel C; Zagon IS; Pearce-Clawson M; McLaughlin PJ
J Neurosci Res; 2022 Feb; 100(2):551-563. PubMed ID: 34821408
[TBL] [Abstract][Full Text] [Related]
13. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
[TBL] [Abstract][Full Text] [Related]
14. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
15. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
[TBL] [Abstract][Full Text] [Related]
16. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
17. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
Hammer LA; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Sep; 98():122-31. PubMed ID: 23973432
[TBL] [Abstract][Full Text] [Related]
18. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
19. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
20. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
